In a live virtual event, Thomas C. Krivak, MD, reviewed the key studies of PARP inhibitor and bevacizumab maintenance in ...

Olaparib, an inhibitor of poly (ADP-ribose) polymerase (PARP), has demonstrated promising outcomes in treating HER2-negative early-stage breast cancer with BRCA mutations. However, a comprehensive ...

President Donald Trump has ordered federal officials to scour monuments, memorials and statues to remove language he says may "inappropriately disparage Americans," as part of his efforts to fight ...

“We’re making dinner together and all of a sudden we hear this name Olaparib come up, so we come round, we watch the television”, said Eva’s husband Peter, who felt a shiver down his spine after ...

In the phase 3 PROpel trial (NCT03732820) patients with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib plus abiraterone in the first-line setting showed significantly ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A first-line regimen involving pembrolizumab (Keytruda) and olaparib (Lynparza) significantly reduced the risk of ...